COCP News and Press, Cocrystal Pharma Inc. From 03/23/22

Commenced enrollment in Phase 1 trial with orally administered, broad-spectrum antiviral agent CC-42344 for the treatment of pandemic and seasonal influenza A Advanced COVID-19 programs with the goal of initiating two Phase 1 trials in 2022 with the intranasal/pulmonary antiviral ...

BOTHELL, Wash., March 22, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that management will participate in the 2022 Virtual Growth Conference, presented by Maxim Group and hosted by M-Vest, being held March 28-30, 2022. Those interested in attending the virtu...

Cocrystal Pharma (NASDAQ:COCP) began dosing in a phase 1 trial of healthy adults evaluating its antiviral CC-42344 to treat pandemic and seasonal influenza A. The company expects to enroll to enroll up to 56 healthy adults at a single site in Australia. Results are expected later this ye...

BOTHELL, Wash., March 10, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces dosing of the first subjects in a Phase 1 clinical trial of healthy adults evaluating its novel, broad-spectrum, orally administe...

BOTHELL, Wash., March 03, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that management will participate in two upcoming investment conferences as follows: Q1 Investor Summit Virtual Small & Micro Cap Conference being held March 8-9. Co...

Cocrystal Makes Progress Against SARS-CoV-2. In November 2021, the SARS-CoV-2 Omicron variant was identified as a new, highly contagious strain. Although less virulent than other strains, its genetic variations allowed it to evade immune protection from current vaccines. Since then, variants h...

Novel broad-spectrum oral lead candidates CDI-988 and CDI- 873 , discovered using Cocrystal’s antiviral drug discovery platform , demonstrate superior in vitro potency against SARS-CoV-2 and activity against all variants of concer...

Response to pre-IND briefing package supports pathway to initiating a Phase 1 clinical study in 2022 BOTHELL, Wash., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) ann...

BOTHELL, Wash., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that management will present a company overview at the H.C. Wainwright BioConnect Virtual Conference being held January 10-13, 202...

Cocrystal Pharma (COCP) cited lab-based studies to indicate that the company’s oral and intranasal/pulmonary main protease inhibitors for COVID-19 showed antiviral effects against the Omicron variant of the virus. Cocrystal (NASDAQ:COCP) said that it would begin Phase 1 studies for COV...